NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA – ExecEdge

Now Reading:

NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA

Exec-Edge

Full Article 50 second read

NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA

50 second read

By Karen Roman

NanoViricides, Inc. (NYSE: NNVC) said the FDA granted “Orphan Drug Designation” to its antiviral drug NV-387 for the treatment of measles, giving the company seven years of market exclusivity after approval and access to tax credits, among other benefits.

There is no approved drug to treat the disease and global cases have increased in recent years due in part to vaccine hesitancy, the company stated.

“NV-387, as an effective drug would be an important tool to fight Measles resurgence in the USA and worldwide, when approved,” said Anil R. Diwan, PhD., NanoViricides President and Executive Chairman.

READ MORE